T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (884)	2/5/2002 3:08:28 PM
From: Icebrg	Read Replies (1) of 2243

>>Please feel free to add to the list>> DOV Pharmaceuticals is lovey-dovey with neurotransmitter receptors. The development-stage firm focuses on therapies primarily for central nervous system conditions. Lead drug candidate NBI-34060 may treat insomnia by targeting the same subset of neurotransmitter receptors affected by Valium and Xanax, but with more specificity to avoid side effects associated with those drugs. DOV is working with Neurocrine Biosciences on the candidate. Biovail licensed cardiovascular candidate Diltiazem's patent from the biotech as part of its ploy to keep Andrx from gaining approval for its generic version of Biovail's blood-pressure drug Tiazac. DOV's 80%-owned joint venture with Elan is developing an anxiety drug.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next